Verum  ||| S:0 E:6 ||| FW
versus  ||| S:6 E:13 ||| FW
sham  ||| S:13 E:18 ||| FW
manual  ||| S:18 E:25 ||| FW
acupuncture  ||| S:25 E:37 ||| FW
for  ||| S:37 E:41 ||| IN
migraine ||| S:41 E:49 ||| NNS
:  ||| S:49 E:51 ||| :
a  ||| S:51 E:53 ||| DT
systematic  ||| S:53 E:64 ||| JJ
review  ||| S:64 E:71 ||| NN
of  ||| S:71 E:74 ||| IN
randomised  ||| S:74 E:85 ||| FW
controlled  ||| S:85 E:96 ||| FW
trials  ||| S:96 E:103 ||| FW
Manual  ||| S:103 E:110 ||| FW
acupuncture  ||| S:110 E:122 ||| FW
( ||| S:122 E:123 ||| -LRB-
MA ||| S:123 E:125 ||| NNP
)  ||| S:125 E:127 ||| -RRB-
is  ||| S:127 E:130 ||| VBZ
commonly  ||| S:130 E:139 ||| RB
used  ||| S:139 E:144 ||| VBN
as  ||| S:144 E:147 ||| IN
a  ||| S:147 E:149 ||| DT
treatment  ||| S:149 E:159 ||| NN
for  ||| S:159 E:163 ||| IN
migraine  ||| S:163 E:172 ||| NN
in  ||| S:172 E:175 ||| IN
China ||| S:175 E:180 ||| NNP
.  ||| S:180 E:182 ||| .
However ||| S:182 E:189 ||| RB
,  ||| S:189 E:191 ||| ,
its  ||| S:191 E:195 ||| PRP$
specific  ||| S:195 E:204 ||| JJ
clinical  ||| S:204 E:213 ||| JJ
effects  ||| S:213 E:221 ||| NNS
have  ||| S:221 E:226 ||| VBP
been  ||| S:226 E:231 ||| VBN
challenged  ||| S:231 E:242 ||| VBN
on  ||| S:242 E:245 ||| IN
the  ||| S:245 E:249 ||| DT
basis  ||| S:249 E:255 ||| NN
that  ||| S:255 E:260 ||| IN
some  ||| S:260 E:265 ||| DT
of  ||| S:265 E:268 ||| IN
its  ||| S:268 E:272 ||| PRP$
effects  ||| S:272 E:280 ||| NNS
may  ||| S:280 E:284 ||| MD
relate  ||| S:284 E:291 ||| VB
to  ||| S:291 E:294 ||| TO
psychological  ||| S:294 E:308 ||| JJ
or  ||| S:308 E:311 ||| NN
' ||| S:311 E:312 ||| POS
placebo ||| S:312 E:319 ||| NN
'  ||| S:319 E:321 ||| POS
mechanisms ||| S:321 E:331 ||| NNS
.  ||| S:331 E:333 ||| .
To  ||| S:333 E:336 ||| TO
identify  ||| S:336 E:345 ||| VB
the  ||| S:345 E:349 ||| DT
effectiveness  ||| S:349 E:363 ||| NN
of  ||| S:363 E:366 ||| IN
verum  ||| S:366 E:372 ||| JJ
MA  ||| S:372 E:375 ||| NNS
compared  ||| S:375 E:384 ||| VBN
with  ||| S:384 E:389 ||| IN
sham  ||| S:389 E:394 ||| JJ
acupuncture  ||| S:394 E:406 ||| NN
for  ||| S:406 E:410 ||| IN
the  ||| S:410 E:414 ||| DT
treatment  ||| S:414 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
migraine ||| S:427 E:435 ||| NN
.  ||| S:435 E:437 ||| .
Eight  ||| S:437 E:443 ||| CD
electronic  ||| S:443 E:454 ||| JJ
databases  ||| S:454 E:464 ||| NN
were  ||| S:464 E:469 ||| VBD
searched  ||| S:469 E:478 ||| VBN
for  ||| S:478 E:482 ||| IN
randomised  ||| S:482 E:493 ||| JJ
controlled  ||| S:493 E:504 ||| JJ
trials  ||| S:504 E:511 ||| NNS
( ||| S:511 E:512 ||| -LRB-
RCTs ||| S:512 E:516 ||| NNP
)  ||| S:516 E:518 ||| -RRB-
evaluating  ||| S:518 E:529 ||| VBG
the  ||| S:529 E:533 ||| DT
effect  ||| S:533 E:540 ||| NN
of  ||| S:540 E:543 ||| IN
verum  ||| S:543 E:549 ||| FW
versus  ||| S:549 E:556 ||| FW
sham  ||| S:556 E:561 ||| FW
MA  ||| S:561 E:564 ||| NNP
on  ||| S:564 E:567 ||| IN
migraine ||| S:567 E:575 ||| NN
.  ||| S:575 E:577 ||| .
The  ||| S:577 E:581 ||| DT
quality  ||| S:581 E:589 ||| NN
of  ||| S:589 E:592 ||| IN
included  ||| S:592 E:601 ||| VBN
trials  ||| S:601 E:608 ||| NNS
was  ||| S:608 E:612 ||| VBD
assessed  ||| S:612 E:621 ||| VBN
using  ||| S:621 E:627 ||| VBG
the  ||| S:627 E:631 ||| DT
' ||| S:631 E:632 ||| POS
risk  ||| S:632 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
bias ||| S:640 E:644 ||| NN
'  ||| S:644 E:646 ||| POS
tool  ||| S:646 E:651 ||| NN
provided  ||| S:651 E:660 ||| VBN
by  ||| S:660 E:663 ||| IN
the  ||| S:663 E:667 ||| DT
Cochrane  ||| S:667 E:676 ||| NNP
Handbook  ||| S:676 E:685 ||| NNP
for  ||| S:685 E:689 ||| IN
Systematic  ||| S:689 E:700 ||| NNP
Review  ||| S:700 E:707 ||| NNP
of  ||| S:707 E:710 ||| IN
Intervention ||| S:710 E:722 ||| NN
.  ||| S:722 E:724 ||| .
RevMan  ||| S:724 E:731 ||| JJ
5.2  ||| S:731 E:735 ||| CD
software  ||| S:735 E:744 ||| NN
was  ||| S:744 E:748 ||| VBD
used  ||| S:748 E:753 ||| VBN
for  ||| S:753 E:757 ||| IN
data  ||| S:757 E:762 ||| NN
analysis ||| S:762 E:770 ||| NN
.  ||| S:770 E:772 ||| .
Ten  ||| S:772 E:776 ||| CD
trials  ||| S:776 E:783 ||| NNS
with  ||| S:783 E:788 ||| IN
997  ||| S:788 E:792 ||| CD
participants  ||| S:792 E:805 ||| NNS
were  ||| S:805 E:810 ||| VBD
included ||| S:810 E:818 ||| VBN
.  ||| S:818 E:820 ||| .
Most  ||| S:820 E:825 ||| JJS
trials  ||| S:825 E:832 ||| NNS
had  ||| S:832 E:836 ||| VBD
high  ||| S:836 E:841 ||| JJ
methodological  ||| S:841 E:856 ||| JJ
quality  ||| S:856 E:864 ||| NN
and  ||| S:864 E:868 ||| CC
were  ||| S:868 E:873 ||| VBD
at  ||| S:873 E:876 ||| IN
low  ||| S:876 E:880 ||| JJ
risk  ||| S:880 E:885 ||| NN
of  ||| S:885 E:888 ||| IN
bias ||| S:888 E:892 ||| NN
.  ||| S:892 E:894 ||| .
Meta-analysis  ||| S:894 E:908 ||| NNP
showed  ||| S:908 E:915 ||| VBD
superior  ||| S:915 E:924 ||| JJ
effects  ||| S:924 E:932 ||| NNS
of  ||| S:932 E:935 ||| IN
verum  ||| S:935 E:941 ||| JJ
MA  ||| S:941 E:944 ||| NN
over  ||| S:944 E:949 ||| IN
sham  ||| S:949 E:954 ||| JJ
acupuncture  ||| S:954 E:966 ||| NN
on  ||| S:966 E:969 ||| IN
the  ||| S:969 E:973 ||| DT
total  ||| S:973 E:979 ||| JJ
effective  ||| S:979 E:989 ||| JJ
rate ||| S:989 E:993 ||| NN
,  ||| S:993 E:995 ||| ,
reflected  ||| S:995 E:1005 ||| VBD
by  ||| S:1005 E:1008 ||| IN
a  ||| S:1008 E:1010 ||| DT
reduction  ||| S:1010 E:1020 ||| NN
in  ||| S:1020 E:1023 ||| IN
the  ||| S:1023 E:1027 ||| DT
' ||| S:1027 E:1028 ||| ''
not  ||| S:1028 E:1032 ||| RB
effective ||| S:1032 E:1041 ||| JJ
'  ||| S:1041 E:1043 ||| POS
rate  ||| S:1043 E:1048 ||| NN
( ||| S:1048 E:1049 ||| -LRB-
relative  ||| S:1049 E:1058 ||| JJ
risk  ||| S:1058 E:1063 ||| NN
( ||| S:1063 E:1064 ||| -LRB-
RR ||| S:1064 E:1066 ||| NNP
)  ||| S:1066 E:1068 ||| -RRB-
0.24 ||| S:1068 E:1072 ||| CD
,  ||| S:1072 E:1074 ||| ,
95 ||| S:1074 E:1076 ||| CD
%  ||| S:1076 E:1078 ||| NN
CI  ||| S:1078 E:1081 ||| NNP
0.15  ||| S:1081 E:1086 ||| CD
to  ||| S:1086 E:1089 ||| TO
0.38 ||| S:1089 E:1093 ||| CD
;  ||| S:1093 E:1095 ||| :
p  ||| S:1095 E:1096 ||| CD
< ||| S:1096 E:1097 ||| SYM
0.0001 ||| S:1097 E:1103 ||| CD
,  ||| S:1103 E:1105 ||| ,
four  ||| S:1105 E:1110 ||| CD
trials ||| S:1110 E:1116 ||| NNS
)  ||| S:1116 E:1118 ||| -RRB-
and  ||| S:1118 E:1122 ||| CC
a  ||| S:1122 E:1124 ||| DT
reduced  ||| S:1124 E:1132 ||| JJ
recurrence  ||| S:1132 E:1143 ||| NN
rate  ||| S:1143 E:1148 ||| NN
( ||| S:1148 E:1149 ||| -LRB-
RR  ||| S:1149 E:1152 ||| NNP
0.47 ||| S:1152 E:1156 ||| NNP
,  ||| S:1156 E:1158 ||| ,
95 ||| S:1158 E:1160 ||| CD
%  ||| S:1160 E:1162 ||| NN
CI  ||| S:1162 E:1165 ||| NNP
0.28  ||| S:1165 E:1170 ||| CD
to  ||| S:1170 E:1173 ||| TO
0.81 ||| S:1173 E:1177 ||| CD
;  ||| S:1177 E:1179 ||| :
p=0.006 ||| S:1179 E:1186 ||| CD
,  ||| S:1186 E:1188 ||| ,
two  ||| S:1188 E:1192 ||| CD
trials ||| S:1192 E:1198 ||| NNS
) ||| S:1198 E:1199 ||| -RRB-
,  ||| S:1199 E:1201 ||| ,
but  ||| S:1201 E:1205 ||| CC
no  ||| S:1205 E:1208 ||| DT
significant  ||| S:1208 E:1220 ||| JJ
differences  ||| S:1220 E:1232 ||| NNS
in  ||| S:1232 E:1235 ||| IN
headache  ||| S:1235 E:1244 ||| JJ
intensity ||| S:1244 E:1253 ||| NN
,  ||| S:1253 E:1255 ||| ,
frequency  ||| S:1255 E:1265 ||| NN
or  ||| S:1265 E:1268 ||| CC
duration ||| S:1268 E:1276 ||| NN
,  ||| S:1276 E:1278 ||| ,
accompanying  ||| S:1278 E:1291 ||| VBG
symptoms  ||| S:1291 E:1300 ||| NNS
and  ||| S:1300 E:1304 ||| CC
use  ||| S:1304 E:1308 ||| NN
of  ||| S:1308 E:1311 ||| IN
medication ||| S:1311 E:1321 ||| NN
.  ||| S:1321 E:1323 ||| .
No  ||| S:1323 E:1326 ||| DT
severe  ||| S:1326 E:1333 ||| JJ
adverse  ||| S:1333 E:1341 ||| JJ
events  ||| S:1341 E:1348 ||| NNS
related  ||| S:1348 E:1356 ||| VBN
to  ||| S:1356 E:1359 ||| TO
acupuncture  ||| S:1359 E:1371 ||| VB
occurred  ||| S:1371 E:1380 ||| VBN
during  ||| S:1380 E:1387 ||| IN
treatment  ||| S:1387 E:1397 ||| NN
with  ||| S:1397 E:1402 ||| IN
either  ||| S:1402 E:1409 ||| DT
verum  ||| S:1409 E:1415 ||| NN
or  ||| S:1415 E:1418 ||| CC
sham  ||| S:1418 E:1423 ||| JJ
MA ||| S:1423 E:1425 ||| NNP
.  ||| S:1425 E:1427 ||| .
Current  ||| S:1427 E:1435 ||| JJ
clinical  ||| S:1435 E:1444 ||| JJ
evidence  ||| S:1444 E:1453 ||| NN
suggests  ||| S:1453 E:1462 ||| VBZ
that  ||| S:1462 E:1467 ||| DT
verum  ||| S:1467 E:1473 ||| JJ
acupuncture  ||| S:1473 E:1485 ||| NN
is  ||| S:1485 E:1488 ||| VBZ
superior  ||| S:1488 E:1497 ||| JJ
to  ||| S:1497 E:1500 ||| TO
sham  ||| S:1500 E:1505 ||| VB
acupuncture  ||| S:1505 E:1517 ||| VBN
in  ||| S:1517 E:1520 ||| IN
migraine ||| S:1520 E:1528 ||| NN
,  ||| S:1528 E:1530 ||| ,
reflected  ||| S:1530 E:1540 ||| VBD
by  ||| S:1540 E:1543 ||| IN
a  ||| S:1543 E:1545 ||| DT
higher  ||| S:1545 E:1552 ||| JJR
total  ||| S:1552 E:1558 ||| JJ
effective  ||| S:1558 E:1568 ||| JJ
rate  ||| S:1568 E:1573 ||| NN
and  ||| S:1573 E:1577 ||| CC
decreased  ||| S:1577 E:1587 ||| VBD
recurrence  ||| S:1587 E:1598 ||| JJ
rate ||| S:1598 E:1602 ||| NN
.  ||| S:1602 E:1604 ||| .
Nevertheless ||| S:1604 E:1616 ||| RB
,  ||| S:1616 E:1618 ||| ,
further  ||| S:1618 E:1626 ||| RB
large-scale  ||| S:1626 E:1638 ||| JJ
RCTs  ||| S:1638 E:1643 ||| NN
with  ||| S:1643 E:1648 ||| IN
a  ||| S:1648 E:1650 ||| DT
rigorous  ||| S:1650 E:1659 ||| JJ
design  ||| S:1659 E:1666 ||| NN
are  ||| S:1666 E:1670 ||| VBP
required  ||| S:1670 E:1679 ||| VBN
to  ||| S:1679 E:1682 ||| TO
confirm  ||| S:1682 E:1690 ||| VB
these  ||| S:1690 E:1696 ||| DT
findings  ||| S:1696 E:1705 ||| NNS
in  ||| S:1705 E:1708 ||| IN
view  ||| S:1708 E:1713 ||| NN
of  ||| S:1713 E:1716 ||| IN
the  ||| S:1716 E:1720 ||| DT
relative  ||| S:1720 E:1729 ||| JJ
paucity  ||| S:1729 E:1737 ||| NN
of  ||| S:1737 E:1740 ||| IN
eligible  ||| S:1740 E:1749 ||| JJ
RCTs  ||| S:1749 E:1754 ||| JJ
and  ||| S:1754 E:1758 ||| CC
small  ||| S:1758 E:1764 ||| JJ
sample  ||| S:1764 E:1771 ||| NN
sizes  ||| S:1771 E:1777 ||| NNS
of  ||| S:1777 E:1780 ||| IN
those  ||| S:1780 E:1786 ||| DT
included ||| S:1786 E:1794 ||| VBN
.  ||| S:1794 E:1796 ||| .
